Park W., Hrycaj P., Jeka S., Kovalenko V., Lysenko G., Miranda P. et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis., 2013, 72 (10): 1605-12.
Yoo D.H., Hrycaj P., Miranda P., Ramiterre E., Piotrowski M., Shevchuk S. et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann. Rheum. Dis., 2013, 72 (10): 1613-20.
Agency EM. CHMP assessment report Flixabi. 2016.
Choe J.Y., Prodanovic N., Niebrzydowski J., Staykov I., Dokoupilova E., Baranauskaite A. et al. A randomised, doubleblind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann. Rheum. Dis., 2017, 76 (1): 58-64.
Jorgensen K.K., Olsen I.C., Goll G.L., Lorentzen M., Bolstad N., Haavardsholm E.A. et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, doubleblind, non-inferiority trial. Lancet, 2017.
Martelli L., Peyrin-Biroulet L. Efficacy, safety and immunogenicity of biosimilars in inflammatory bowel diseases: A systematic review. Curr. Med. Chem., 2016.
Danese S., Fiorino G., Raine T., Ferrante M., Kemp K., Kierkus J. et al. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. J. Crohns Colitis., 2017, 11 (1): 26-34.
Vermeire S., Louis E., Dewit O., Franchimont D., Moreels T., Ferrante M. et al. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD). Acta Gastroenterol. Belg., 2015, 78 (1): 26-9.
Weise M., Kurki P., Wolff-Holz E., Bielsky M.C., Schneider C.K. Biosimilars: the science of extrapolation. Blood, 2014, 124 (22): 3191-6.
Commission E. What you need to know about biosimilar medicinal products. 2013.
Jung Y.S., Park D.I., Kim Y.H., Lee J.H., Seo P.J., Cheon J.H. et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J. Gastroenterol. Hepatol., 2015, 30 (12): 1705-12.
Smits L.J., Derikx L.A., de Jong D.J., Boshuizen R.S., van Esch A.A., Drenth J.P. et al. Clinical Outcomes Following a Switch from Remicade(R) to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. J. Crohns Colitis, 2016, 10 (11): 1287-93.
Park S.H., Kim Y.H., Lee J.H., Kwon H.J., Lee S.H., Park D.I. et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol. Hepatol., 2015, 9 Suppl 1: 35-44.
Sieczkowska J., Jarzebicka D., Banaszkiewicz A., Plocek A., Gawronska A., Toporowska-Kowalska E. et al. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations. J. Crohns Colitis., 2016, 10 (2): 127-32.
Fiorino G., Manetti N., Armuzzi A., Orlando A., Variola A., Bonovas S. et al. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm. Bowel Dis., 2017, 23 (2): 233-43.
Farkas K., Rutka M., Golovics P.A., Vegh Z., Lovasz B.D., Nyari T. et al. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis. J. Crohns Colitis., 2016, 10 (11): 1273-
Gecse K.B., Lovasz B.D., Farkas K., Banai J., Bene L., Gasztonyi B. et al. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort. J. Crohns Colitis., 2016, 10 (2): 133-40.
Jahnsen J., Detlie T.E., Vatn S., Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Rev. Gastroenterol. Hepatol., 2015, 9 Suppl 1: 45-52.
Jha A., Upton A., Dunlop W.C., Akehurst R. The Budget Impact of Biosimilar Infliximab (Remsima(R)) for the Treatment of Autoimmune Diseases in Five European Countries. Adv. Ther., 2015, 32 (8): 742-56.
Razanskaite V., Bettey M., Downey L., Wright J., Callaghan J., Rush M. et al. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme. J. Crohns Colitis., 2017.
Kim Y.H. Y.B., Pesegova M., Alexeeva O., Osipenko M., Lahat A. et al. Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: early efficacy and safety results. Journal of Crohn’s and Colitis, 2017, 11 (Supplement 1): S62.
Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial” (SIMILAR).
Rojas J.R., Taylor R.P., Cunningham M.R., Rutkoski T.J., Vennarini J., Jang H. et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J. Pharmacol. Exp. Ther., 2005, 313 (2): 578-85.
Nanda K.S., Cheifetz A.S., Moss A.C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am. J. Gastroenterol., 2013, 108 (1): 40-7; quiz 8.
Vande Casteele N., Khanna R., Levesque B.G., Stitt L., Zou G.Y., Singh S. et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut, 2015, 64 (10): 1539-45.
Park W., Yoo D.H., Miranda P., Brzosko M., Wiland P., Gutierrez-Urena S. et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann. Rheum. Dis., 2017, 76 (2): 346-54.
Yoo D.H., Prodanovic N., Jaworski J., Miranda P., Ramiterre E., Lanzon A. et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann. Rheum. Dis., 2017, 76 (2): 355-63.
Jørgensen K., OI G.G. et al. Biosimilar infliximab [CT-P13] is not inferior to originator infliximab: results from the 52-week randomised NORSWITCH trial. UEG, Vienna 2016.
Ben-Horin S., Yavzori M., Benhar I., Fudim E., Picard O., Ungar B. et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut, 2016, 65 (7): 1132-8.
KCE. Barriers and opportunities for the uptake of biosimilar medecines in belgium (Report 199). 2013.
EuropaBio BMGE. European Commission Q&A -What I need to know about Biosimilar Medicine – Information for patients.
